NCT00959647 - A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions

Ovarian CancerBasal Cell CarcinomaMetastatic Colorectal Cancer

Interventions

DRUG

Vismodegib

Vismodegib was supplied in capsules.

DRUG

FOLFOX

FOLFOX (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and oxaliplatin \[OX\]) was supplied as solutions for intravenous administration.

DRUG

FOLFIRI

FOLFIRI (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and irinotecan \[IRI\]) was supplied as solutions for intravenous administration.

DRUG

Bevacizumab

Bevacizumab was supplied as a solution for intravenous administration.

Trial Locations (10)

21231

Baltimore

45242

Cincinnati

48201

Detroit

77030

Houston

85258

Scottsdale

89106

Las Vegas

92262

Palm Springs

94305

Stanford

94609

Oakland

48109-0934

Ann Arbor